

Global Tafasitamab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

<https://marketpublishers.com/r/G61E2ACD0B6DEN.html>

Date: June 2026

Pages: 84

Price: US\$ 3,480.00 (Single User License)

ID: G61E2ACD0B6DEN

Abstracts

According to our (Global Info Research) latest study, the global Tafasitamab market size was valued at US\$ 350 million in 2025 and is forecast to a readjusted size of US\$ 812 million by 2032 with a CAGR of 11.5% during review period.

Tafasitamab is a humanized CD19-targeted monoclonal antibody primarily used in the treatment of B-cell malignancies. It specifically binds to the CD19 antigen expressed on the surface of B cells, inducing antibody-dependent cellular cytotoxicity (ADCC) and other immune-mediated mechanisms, thereby promoting the elimination of malignant B cells. Tafasitamab is typically used in combination with immunomodulatory agents such as lenalidomide for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It has significant clinical value in the field of hematologic cancer targeted therapy. In 2025, global production of tafasitamab reached approximately 150,000 units.

Tafasitamab, as a CD19-targeted monoclonal antibody, occupies an important niche in the treatment market for B-cell non-Hodgkin lymphoma, particularly in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). With the steady increase in the global incidence of hematologic malignancies and the growing demand for novel immuno-targeted therapies, the CD19-targeted drug market is gradually expanding. Tafasitamab has demonstrated clinical efficacy in combination with lenalidomide, enabling it to gain guideline recommendations and improve its clinical penetration. From a competitive landscape perspective, this field is not only dominated by long-established CD20 monoclonal antibodies such as rituximab, but also faces competitive pressure from emerging CD19/CD79b-targeted therapies. Looking ahead, with the accumulation of real-world evidence, expansion of indications, and commercialization in emerging markets, the market size of tafasitamab is expected to maintain steady growth, continuing to play an important role in the precision treatment landscape of B-cell

lymphoma.

This report is a detailed and comprehensive analysis for global Tafasitamab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Tafasitamab market size and forecasts, in consumption value (\$ Million), sales quantity (Units), and average selling prices (US\$/Unit), 2021-2032

Global Tafasitamab market size and forecasts by region and country, in consumption value (\$ Million), sales quantity (Units), and average selling prices (US\$/Unit), 2021-2032

Global Tafasitamab market size and forecasts, by Type and by Application, in consumption value (\$ Million), sales quantity (Units), and average selling prices (US\$/Unit), 2021-2032

Global Tafasitamab market shares of main players, shipments in revenue (\$ Million), sales quantity (Units), and ASP (US\$/Unit), 2021-2026

The Primary Objectives in This Report Are:

- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Tafasitamab
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace

This report profiles key players in the global Tafasitamab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product

portfolio, geographical presence, and key developments. Key companies covered as a part of this study include MorphoSys AG, Incyte Corporation, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Tafasitamab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Combination With Immunomodulatory Agents (Such As Lenalidomide)

Combination With Chemotherapy Or Other Targeted Therapies

Market segment by Specification

200 mg / vial

800 mg/vial

Market segment by Production Technology

Innovator

Generic

Market segment by Dosage Form

Lyophilized Powder for Injection

Injection Solution

Market segment by Application

Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

B-Cell Non-Hodgkin Lymphoma (B-NHL)

CD19-Positive Hematologic Malignancies

Precision Hematologic Cancer Therapy

Others

Major players covered

MorphoSys AG

Incyte Corporation

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Tafasitamab product scope, market overview, market estimation

caveats and base year.

Chapter 2, to profile the top manufacturers of Tafasitamab, with price, sales quantity, revenue, and global market share of Tafasitamab from 2021 to 2026.

Chapter 3, the Tafasitamab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Tafasitamab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026. and Tafasitamab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Tafasitamab.

Chapter 14 and 15, to describe Tafasitamab sales channel, distributors, customers, research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope

1.2 Market Estimation Caveats and Base Year

1.3 Market Analysis by Type

1.3.1 Overview: Global Tafasitamab Consumption Value by Type: 2021 Versus 2025 Versus 2032

1.3.2 Combination With Immunomodulatory Agents (Such As Lenalidomide)

1.3.3 Combination With Chemotherapy Or Other Targeted Therapies

1.4 Market Analysis by Specification

1.4.1 Overview: Global Tafasitamab Consumption Value by Specification: 2021 Versus 2025 Versus 2032

1.4.2 200 mg / vial

1.4.3 800 mg/vial

1.5 Market Analysis by Production Technology

1.5.1 Overview: Global Tafasitamab Consumption Value by Production Technology: 2021 Versus 2025 Versus 2032

1.5.2 Innovator

1.5.3 Generic

1.6 Market Analysis by Dosage Form

1.6.1 Overview: Global Tafasitamab Consumption Value by Dosage Form: 2021 Versus 2025 Versus 2032

1.6.2 Lyophilized Powder for Injection

1.6.3 Injection Solution

1.7 Market Analysis by Application

1.7.1 Overview: Global Tafasitamab Consumption Value by Application: 2021 Versus 2025 Versus 2032

1.7.2 Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

1.7.3 B-Cell Non-Hodgkin Lymphoma (B-NHL)

1.7.4 CD19-Positive Hematologic Malignancies

1.7.5 Precision Hematologic Cancer Therapy

1.7.6 Others

1.8 Global Tafasitamab Market Size & Forecast

1.8.1 Global Tafasitamab Consumption Value (2021 & 2025 & 2032)

1.8.2 Global Tafasitamab Sales Quantity (2021-2032)

1.8.3 Global Tafasitamab Average Price (2021-2032)

2 MANUFACTURERS PROFILES

2.1 MorphoSys AG

2.1.1 MorphoSys AG Details

2.1.2 MorphoSys AG Major Business

2.1.3 MorphoSys AG Tafasitamab Product and Services

2.1.4 MorphoSys AG Tafasitamab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.1.5 MorphoSys AG Recent Developments/Updates

2.2 Incyte Corporation

2.2.1 Incyte Corporation Details

2.2.2 Incyte Corporation Major Business

2.2.3 Incyte Corporation Tafasitamab Product and Services

2.2.4 Incyte Corporation Tafasitamab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.2.5 Incyte Corporation Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: TAFASITAMAB BY MANUFACTURER

3.1 Global Tafasitamab Sales Quantity by Manufacturer (2021-2026)

3.2 Global Tafasitamab Revenue by Manufacturer (2021-2026)

3.3 Global Tafasitamab Average Price by Manufacturer (2021-2026)

3.4 Market Share Analysis (2025)

3.4.1 Producer Shipments of Tafasitamab by Manufacturer Revenue (\$MM) and Market Share (%): 2025

3.4.2 Top 3 Tafasitamab Manufacturer Market Share in 2025

3.4.3 Top 6 Tafasitamab Manufacturer Market Share in 2025

3.5 Tafasitamab Market: Overall Company Footprint Analysis

3.5.1 Tafasitamab Market: Region Footprint

3.5.2 Tafasitamab Market: Company Product Type Footprint

3.5.3 Tafasitamab Market: Company Product Application Footprint

3.6 New Market Entrants and Barriers to Market Entry

3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

4.1 Global Tafasitamab Market Size by Region

4.1.1 Global Tafasitamab Sales Quantity by Region (2021-2032)

4.1.2 Global Tafasitamab Consumption Value by Region (2021-2032)

- 4.1.3 Global Tafasitamab Average Price by Region (2021-2032)
- 4.2 North America Tafasitamab Consumption Value (2021-2032)
- 4.3 Europe Tafasitamab Consumption Value (2021-2032)
- 4.4 Asia-Pacific Tafasitamab Consumption Value (2021-2032)
- 4.5 South America Tafasitamab Consumption Value (2021-2032)
- 4.6 Middle East & Africa Tafasitamab Consumption Value (2021-2032)

5 MARKET SEGMENT BY TYPE

- 5.1 Global Tafasitamab Sales Quantity by Type (2021-2032)
- 5.2 Global Tafasitamab Consumption Value by Type (2021-2032)
- 5.3 Global Tafasitamab Average Price by Type (2021-2032)

6 MARKET SEGMENT BY APPLICATION

- 6.1 Global Tafasitamab Sales Quantity by Application (2021-2032)
- 6.2 Global Tafasitamab Consumption Value by Application (2021-2032)
- 6.3 Global Tafasitamab Average Price by Application (2021-2032)

7 NORTH AMERICA

- 7.1 North America Tafasitamab Sales Quantity by Type (2021-2032)
- 7.2 North America Tafasitamab Sales Quantity by Application (2021-2032)
- 7.3 North America Tafasitamab Market Size by Country
 - 7.3.1 North America Tafasitamab Sales Quantity by Country (2021-2032)
 - 7.3.2 North America Tafasitamab Consumption Value by Country (2021-2032)
 - 7.3.3 United States Market Size and Forecast (2021-2032)
 - 7.3.4 Canada Market Size and Forecast (2021-2032)
 - 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 EUROPE

- 8.1 Europe Tafasitamab Sales Quantity by Type (2021-2032)
- 8.2 Europe Tafasitamab Sales Quantity by Application (2021-2032)
- 8.3 Europe Tafasitamab Market Size by Country
 - 8.3.1 Europe Tafasitamab Sales Quantity by Country (2021-2032)
 - 8.3.2 Europe Tafasitamab Consumption Value by Country (2021-2032)
 - 8.3.3 Germany Market Size and Forecast (2021-2032)
 - 8.3.4 France Market Size and Forecast (2021-2032)

- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)

9 ASIA-PACIFIC

- 9.1 Asia-Pacific Tafasitamab Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Tafasitamab Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Tafasitamab Market Size by Region
 - 9.3.1 Asia-Pacific Tafasitamab Sales Quantity by Region (2021-2032)
 - 9.3.2 Asia-Pacific Tafasitamab Consumption Value by Region (2021-2032)
 - 9.3.3 China Market Size and Forecast (2021-2032)
 - 9.3.4 Japan Market Size and Forecast (2021-2032)
 - 9.3.5 South Korea Market Size and Forecast (2021-2032)
 - 9.3.6 India Market Size and Forecast (2021-2032)
 - 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
 - 9.3.8 Australia Market Size and Forecast (2021-2032)

10 SOUTH AMERICA

- 10.1 South America Tafasitamab Sales Quantity by Type (2021-2032)
- 10.2 South America Tafasitamab Sales Quantity by Application (2021-2032)
- 10.3 South America Tafasitamab Market Size by Country
 - 10.3.1 South America Tafasitamab Sales Quantity by Country (2021-2032)
 - 10.3.2 South America Tafasitamab Consumption Value by Country (2021-2032)
 - 10.3.3 Brazil Market Size and Forecast (2021-2032)
 - 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 MIDDLE EAST & AFRICA

- 11.1 Middle East & Africa Tafasitamab Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Tafasitamab Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Tafasitamab Market Size by Country
 - 11.3.1 Middle East & Africa Tafasitamab Sales Quantity by Country (2021-2032)
 - 11.3.2 Middle East & Africa Tafasitamab Consumption Value by Country (2021-2032)
 - 11.3.3 Turkey Market Size and Forecast (2021-2032)
 - 11.3.4 Egypt Market Size and Forecast (2021-2032)
 - 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
 - 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 MARKET DYNAMICS

- 12.1 Tafasitamab Market Drivers
- 12.2 Tafasitamab Market Restraints
- 12.3 Tafasitamab Trends Analysis
- 12.4 Porters Five Forces Analysis
 - 12.4.1 Threat of New Entrants
 - 12.4.2 Bargaining Power of Suppliers
 - 12.4.3 Bargaining Power of Buyers
 - 12.4.4 Threat of Substitutes
 - 12.4.5 Competitive Rivalry

13 RAW MATERIAL AND INDUSTRY CHAIN

- 13.1 Raw Material of Tafasitamab and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Tafasitamab
- 13.3 Tafasitamab Production Process
- 13.4 Industry Value Chain Analysis

14 SHIPMENTS BY DISTRIBUTION CHANNEL

- 14.1 Sales Channel
 - 14.1.1 Direct to End-User
 - 14.1.2 Distributors
- 14.2 Tafasitamab Typical Distributors
- 14.3 Tafasitamab Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

- 16.1 Methodology
- 16.2 Research Process and Data Source
- 16.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Tafasitamab Consumption Value by Type, (USD Million), 2021 & 2025 & 2032

Table 2. Global Tafasitamab Consumption Value by Specification, (USD Million), 2021 & 2025 & 2032

Table 3. Global Tafasitamab Consumption Value by Production Technology, (USD Million), 2021 & 2025 & 2032

Table 4. Global Tafasitamab Consumption Value by Dosage Form, (USD Million), 2021 & 2025 & 2032

Table 5. Global Tafasitamab Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Table 6. MorphoSys AG Basic Information, Manufacturing Base and Competitors

Table 7. MorphoSys AG Major Business

Table 8. MorphoSys AG Tafasitamab Product and Services

Table 9. MorphoSys AG Tafasitamab Sales Quantity (Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 10. MorphoSys AG Recent Developments/Updates

Table 11. Incyte Corporation Basic Information, Manufacturing Base and Competitors

Table 12. Incyte Corporation Major Business

Table 13. Incyte Corporation Tafasitamab Product and Services

Table 14. Incyte Corporation Tafasitamab Sales Quantity (Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 15. Incyte Corporation Recent Developments/Updates

Table 16. Global Tafasitamab Sales Quantity by Manufacturer (2021-2026) & (Units)

Table 17. Global Tafasitamab Revenue by Manufacturer (2021-2026) & (USD Million)

Table 18. Global Tafasitamab Average Price by Manufacturer (2021-2026) & (US\$/Unit)

Table 19. Market Position of Manufacturers in Tafasitamab, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025

Table 20. Head Office and Tafasitamab Production Site of Key Manufacturer

Table 21. Tafasitamab Market: Company Product Type Footprint

Table 22. Tafasitamab Market: Company Product Application Footprint

Table 23. Tafasitamab New Market Entrants and Barriers to Market Entry

Table 24. Tafasitamab Mergers, Acquisition, Agreements, and Collaborations

Table 25. Global Tafasitamab Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR

Table 26. Global Tafasitamab Sales Quantity by Region (2021-2026) & (Units)

Table 27. Global Tafasitamab Sales Quantity by Region (2027-2032) & (Units)

Table 28. Global Tafasitamab Consumption Value by Region (2021-2026) & (USD Million)

Table 29. Global Tafasitamab Consumption Value by Region (2027-2032) & (USD Million)

Table 30. Global Tafasitamab Average Price by Region (2021-2026) & (US\$/Unit)

Table 31. Global Tafasitamab Average Price by Region (2027-2032) & (US\$/Unit)

Table 32. Global Tafasitamab Sales Quantity by Type (2021-2026) & (Units)

Table 33. Global Tafasitamab Sales Quantity by Type (2027-2032) & (Units)

Table 34. Global Tafasitamab Consumption Value by Type (2021-2026) & (USD Million)

Table 35. Global Tafasitamab Consumption Value by Type (2027-2032) & (USD Million)

Table 36. Global Tafasitamab Average Price by Type (2021-2026) & (US\$/Unit)

Table 37. Global Tafasitamab Average Price by Type (2027-2032) & (US\$/Unit)

Table 38. Global Tafasitamab Sales Quantity by Application (2021-2026) & (Units)

Table 39. Global Tafasitamab Sales Quantity by Application (2027-2032) & (Units)

Table 40. Global Tafasitamab Consumption Value by Application (2021-2026) & (USD Million)

Table 41. Global Tafasitamab Consumption Value by Application (2027-2032) & (USD Million)

Table 42. Global Tafasitamab Average Price by Application (2021-2026) & (US\$/Unit)

Table 43. Global Tafasitamab Average Price by Application (2027-2032) & (US\$/Unit)

Table 44. North America Tafasitamab Sales Quantity by Type (2021-2026) & (Units)

Table 45. North America Tafasitamab Sales Quantity by Type (2027-2032) & (Units)

Table 46. North America Tafasitamab Sales Quantity by Application (2021-2026) & (Units)

Table 47. North America Tafasitamab Sales Quantity by Application (2027-2032) & (Units)

Table 48. North America Tafasitamab Sales Quantity by Country (2021-2026) & (Units)

Table 49. North America Tafasitamab Sales Quantity by Country (2027-2032) & (Units)

Table 50. North America Tafasitamab Consumption Value by Country (2021-2026) & (USD Million)

Table 51. North America Tafasitamab Consumption Value by Country (2027-2032) & (USD Million)

Table 52. Europe Tafasitamab Sales Quantity by Type (2021-2026) & (Units)

Table 53. Europe Tafasitamab Sales Quantity by Type (2027-2032) & (Units)

Table 54. Europe Tafasitamab Sales Quantity by Application (2021-2026) & (Units)

Table 55. Europe Tafasitamab Sales Quantity by Application (2027-2032) & (Units)

Table 56. Europe Tafasitamab Sales Quantity by Country (2021-2026) & (Units)

Table 57. Europe Tafasitamab Sales Quantity by Country (2027-2032) & (Units)

Table 58. Europe Tafasitamab Consumption Value by Country (2021-2026) & (USD Million)

Table 59. Europe Tafasitamab Consumption Value by Country (2027-2032) & (USD Million)

Table 60. Asia-Pacific Tafasitamab Sales Quantity by Type (2021-2026) & (Units)

Table 61. Asia-Pacific Tafasitamab Sales Quantity by Type (2027-2032) & (Units)

Table 62. Asia-Pacific Tafasitamab Sales Quantity by Application (2021-2026) & (Units)

Table 63. Asia-Pacific Tafasitamab Sales Quantity by Application (2027-2032) & (Units)

Table 64. Asia-Pacific Tafasitamab Sales Quantity by Region (2021-2026) & (Units)

Table 65. Asia-Pacific Tafasitamab Sales Quantity by Region (2027-2032) & (Units)

Table 66. Asia-Pacific Tafasitamab Consumption Value by Region (2021-2026) & (USD Million)

Table 67. Asia-Pacific Tafasitamab Consumption Value by Region (2027-2032) & (USD Million)

Table 68. South America Tafasitamab Sales Quantity by Type (2021-2026) & (Units)

Table 69. South America Tafasitamab Sales Quantity by Type (2027-2032) & (Units)

Table 70. South America Tafasitamab Sales Quantity by Application (2021-2026) & (Units)

Table 71. South America Tafasitamab Sales Quantity by Application (2027-2032) & (Units)

Table 72. South America Tafasitamab Sales Quantity by Country (2021-2026) & (Units)

Table 73. South America Tafasitamab Sales Quantity by Country (2027-2032) & (Units)

Table 74. South America Tafasitamab Consumption Value by Country (2021-2026) & (USD Million)

Table 75. South America Tafasitamab Consumption Value by Country (2027-2032) & (USD Million)

Table 76. Middle East & Africa Tafasitamab Sales Quantity by Type (2021-2026) & (Units)

Table 77. Middle East & Africa Tafasitamab Sales Quantity by Type (2027-2032) & (Units)

Table 78. Middle East & Africa Tafasitamab Sales Quantity by Application (2021-2026) & (Units)

Table 79. Middle East & Africa Tafasitamab Sales Quantity by Application (2027-2032) & (Units)

Table 80. Middle East & Africa Tafasitamab Sales Quantity by Country (2021-2026) & (Units)

Table 81. Middle East & Africa Tafasitamab Sales Quantity by Country (2027-2032) & (Units)

Table 82. Middle East & Africa Tafasitamab Consumption Value by Country

(2021-2026) & (USD Million)

Table 83. Middle East & Africa Tafasitamab Consumption Value by Country

(2027-2032) & (USD Million)

Table 84. Tafasitamab Raw Material

Table 85. Key Manufacturers of Tafasitamab Raw Materials

Table 86. Tafasitamab Typical Distributors

Table 87. Tafasitamab Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Tafasitamab Picture

Figure 2. Global Tafasitamab Revenue by Type, (USD Million), 2021 & 2025 & 2032

Figure 3. Global Tafasitamab Revenue Market Share by Type in 2025

Figure 4. Combination With Immunomodulatory Agents (Such As Lenalidomide)

Examples

Figure 5. Combination With Chemotherapy Or Other Targeted Therapies Examples

Figure 6. Global Tafasitamab Revenue by Specification, (USD Million), 2021 & 2025 & 2032

Figure 7. Global Tafasitamab Revenue Market Share by Specification in 2025

Figure 8. 200 mg / vial Examples

Figure 9. 800 mg/vial Examples

Figure 10. Global Tafasitamab Revenue by Production Technology, (USD Million), 2021 & 2025 & 2032

Figure 11. Global Tafasitamab Revenue Market Share by Production Technology in 2025

Figure 12. Innovator Examples

Figure 13. Generic Examples

Figure 14. Global Tafasitamab Revenue by Dosage Form, (USD Million), 2021 & 2025 & 2032

Figure 15. Global Tafasitamab Revenue Market Share by Dosage Form in 2025

Figure 16. Lyophilized Powder for Injection Examples

Figure 17. Injection Solution Examples

Figure 18. Global Tafasitamab Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Figure 19. Global Tafasitamab Revenue Market Share by Application in 2025

Figure 20. Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Examples

Figure 21. B-Cell Non-Hodgkin Lymphoma (B-NHL) Examples

Figure 22. CD19-Positive Hematologic Malignancies Examples

Figure 23. Precision Hematologic Cancer Therapy Examples

Figure 24. Others Examples

Figure 25. Global Tafasitamab Consumption Value, (USD Million): 2021 & 2025 & 2032

Figure 26. Global Tafasitamab Consumption Value and Forecast (2021-2032) & (USD Million)

Figure 27. Global Tafasitamab Sales Quantity (2021-2032) & (Units)

- Figure 28. Global Tafasitamab Price (2021-2032) & (US\$/Unit)
- Figure 29. Global Tafasitamab Sales Quantity Market Share by Manufacturer in 2025
- Figure 30. Global Tafasitamab Revenue Market Share by Manufacturer in 2025
- Figure 31. Producer Shipments of Tafasitamab by Manufacturer Sales (\$MM) and Market Share (%): 2025
- Figure 32. Top 3 Tafasitamab Manufacturer (Revenue) Market Share in 2025
- Figure 33. Top 6 Tafasitamab Manufacturer (Revenue) Market Share in 2025
- Figure 34. Global Tafasitamab Sales Quantity Market Share by Region (2021-2032)
- Figure 35. Global Tafasitamab Consumption Value Market Share by Region (2021-2032)
- Figure 36. North America Tafasitamab Consumption Value (2021-2032) & (USD Million)
- Figure 37. Europe Tafasitamab Consumption Value (2021-2032) & (USD Million)
- Figure 38. Asia-Pacific Tafasitamab Consumption Value (2021-2032) & (USD Million)
- Figure 39. South America Tafasitamab Consumption Value (2021-2032) & (USD Million)
- Figure 40. Middle East & Africa Tafasitamab Consumption Value (2021-2032) & (USD Million)
- Figure 41. Global Tafasitamab Sales Quantity Market Share by Type (2021-2032)
- Figure 42. Global Tafasitamab Consumption Value Market Share by Type (2021-2032)
- Figure 43. Global Tafasitamab Average Price by Type (2021-2032) & (US\$/Unit)
- Figure 44. Global Tafasitamab Sales Quantity Market Share by Application (2021-2032)
- Figure 45. Global Tafasitamab Revenue Market Share by Application (2021-2032)
- Figure 46. Global Tafasitamab Average Price by Application (2021-2032) & (US\$/Unit)
- Figure 47. North America Tafasitamab Sales Quantity Market Share by Type (2021-2032)
- Figure 48. North America Tafasitamab Sales Quantity Market Share by Application (2021-2032)
- Figure 49. North America Tafasitamab Sales Quantity Market Share by Country (2021-2032)
- Figure 50. North America Tafasitamab Consumption Value Market Share by Country (2021-2032)
- Figure 51. United States Tafasitamab Consumption Value (2021-2032) & (USD Million)
- Figure 52. Canada Tafasitamab Consumption Value (2021-2032) & (USD Million)
- Figure 53. Mexico Tafasitamab Consumption Value (2021-2032) & (USD Million)
- Figure 54. Europe Tafasitamab Sales Quantity Market Share by Type (2021-2032)
- Figure 55. Europe Tafasitamab Sales Quantity Market Share by Application (2021-2032)
- Figure 56. Europe Tafasitamab Sales Quantity Market Share by Country (2021-2032)
- Figure 57. Europe Tafasitamab Consumption Value Market Share by Country (2021-2032)

Figure 58. Germany Tafasitamab Consumption Value (2021-2032) & (USD Million)

Figure 59. France Tafasitamab Consumption Value (2021-2032) & (USD Million)

Figure 60. United Kingdom Tafasitamab Consumption Value (2021-2032) & (USD Million)

Figure 61. Russia Tafasitamab Consumption Value (2021-2032) & (USD Million)

Figure 62. Italy Tafasitamab Consumption Value (2021-2032) & (USD Million)

Figure 63. Asia-Pacific Tafasitamab Sales Quantity Market Share by Type (2021-2032)

Figure 64. Asia-Pacific Tafasitamab Sales Quantity Market Share by Application (2021-2032)

Figure 65. Asia-Pacific Tafasitamab Sales Quantity Market Share by Region (2021-2032)

Figure 66. Asia-Pacific Tafasitamab Consumption Value Market Share by Region (2021-2032)

Figure 67. China Tafasitamab Consumption Value (2021-2032) & (USD Million)

Figure 68. Japan Tafasitamab Consumption Value (2021-2032) & (USD Million)

Figure 69. South Korea Tafasitamab Consumption Value (2021-2032) & (USD Million)

Figure 70. India Tafasitamab Consumption Value (2021-2032) & (USD Million)

Figure 71. Southeast Asia Tafasitamab Consumption Value (2021-2032) & (USD Million)

Figure 72. Australia Tafasitamab Consumption Value (2021-2032) & (USD Million)

Figure 73. South America Tafasitamab Sales Quantity Market Share by Type (2021-2032)

Figure 74. South America Tafasitamab Sales Quantity Market Share by Application (2021-2032)

Figure 75. South America Tafasitamab Sales Quantity Market Share by Country (2021-2032)

Figure 76. South America Tafasitamab Consumption Value Market Share by Country (2021-2032)

Figure 77. Brazil Tafasitamab Consumption Value (2021-2032) & (USD Million)

Figure 78. Argentina Tafasitamab Consumption Value (2021-2032) & (USD Million)

Figure 79. Middle East & Africa Tafasitamab Sales Quantity Market Share by Type (2021-2032)

Figure 80. Middle East & Africa Tafasitamab Sales Quantity Market Share by Application (2021-2032)

Figure 81. Middle East & Africa Tafasitamab Sales Quantity Market Share by Country (2021-2032)

Figure 82. Middle East & Africa Tafasitamab Consumption Value Market Share by Country (2021-2032)

Figure 83. Turkey Tafasitamab Consumption Value (2021-2032) & (USD Million)

- Figure 84. Egypt Tafasitamab Consumption Value (2021-2032) & (USD Million)
- Figure 85. Saudi Arabia Tafasitamab Consumption Value (2021-2032) & (USD Million)
- Figure 86. South Africa Tafasitamab Consumption Value (2021-2032) & (USD Million)
- Figure 87. Tafasitamab Market Drivers
- Figure 88. Tafasitamab Market Restraints
- Figure 89. Tafasitamab Market Trends
- Figure 90. Porters Five Forces Analysis
- Figure 91. Manufacturing Cost Structure Analysis of Tafasitamab in 2025
- Figure 92. Manufacturing Process Analysis of Tafasitamab
- Figure 93. Tafasitamab Industrial Chain
- Figure 94. Sales Channel: Direct to End-User vs Distributors
- Figure 95. Direct Channel Pros & Cons
- Figure 96. Indirect Channel Pros & Cons
- Figure 97. Methodology
- Figure 98. Research Process and Data Source

I would like to order

Product name: Global Tafasitamab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Product link: <https://marketpublishers.com/r/G61E2ACD0B6DEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G61E2ACD0B6DEN.html>